Lymphatic system

MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

Retrieved on: 
Monday, February 5, 2024
Partnership, Telehealth, Male, TRT, Erectile dysfunction, Safety, Patient, FDA, Marketing, Pharmacy, Testosterone, Lymphatic system, Liver, Barstool Sports, Schedule, Pharmaceutical industry

Dallas, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce that it is offering 2 months of free ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ (“PRIME”) (a $498 value) for the first 1,000 male subscribers who express interest in subscribing to the oral testosterone replacement protocol.

Key Points: 
  • Those interested in taking advantage of this exclusive offer simply need to visit the sign-up page at https://www.mangorx.com/prime-sign-up/ and submit basic demographic information.
  • Interested subscribers will also be prompted to preorder a minimally invasive FDA approved at-home blood collection test kit through their nationwide lab partnership with Trybe Labs , which is being offered to MangoRx subscribers at preferred discounted prices.
  • ‘PRIME’, by MangoRx, powered by Kyzatrex®️ delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.
  • PRIME will be available to MangoRx customers at a price of $199/month with eligibility to receive an additional 10% discount per month if subscribed to another MangoRx product (e.g.

MangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11

Retrieved on: 
Friday, January 19, 2024
Entrepreneurship, Barstool Sports, Internet, Bowl game, Social media, TRT, Radio, Partnership, Super Bowl, Marquee, Softgel, Lymphatic system, FDA, Erectile dysfunction, Running, Liver, Marketing, Testosterone, Pharmaceutical industry

 Dallas, Texas, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (“GROW”) and erectile dysfunction (“ED”) drug (“Mango”), is excited to announce that it will be a Marquee Sponsor for Barstool Sports’ week-long programming schedule surrounding the Big Game in Las Vegas on Sunday, Feb 11, 2024.

Key Points: 
  • In addition, as a Marquee Sponsor, MangoRx will be prominently featured on the Barstool Podcasts starting the week of January 22nd and running through March 15th with an estimated number of over 7 million views and impressions.
  • Dave Portnoy, one of the most recognizable faces in the American sports media industry, founded Barstool Sports, growing the brand into the multi-million-dollar preeminent digital sports media presence.
  • KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.
  • KYZATREX is delivered as a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.

Children's Hospital of Philadelphia Experts Showcase Frontier Program at Arab Health Exhibition

Retrieved on: 
Monday, January 29, 2024
Health care, Patient, Artery, Research, Chiari malformation, CHOP, Vein, Health, Arab Health, Partnership, Children's Hospital of Philadelphia, Malignancy, Business, Gravity anomaly, Glomus tumor, Congress, Hospital, Lymphatic system, Pain, EHS, Vascular anomaly, Deformity, Nursing

PHILADELPHIA, Jan. 29, 2024 /PRNewswire/ -- Showcasing its longstanding partnership with the United Arab Emirates (UAE) Emirates Health Services (EHS), Children's Hospital of Philadelphia (CHOP) will exhibit thought-leading clinical research in the EHS booth at the Arab Health 2024 Exhibition and Congress , taking place this week in Dubai.

Key Points: 
  • PHILADELPHIA, Jan. 29, 2024 /PRNewswire/ -- Showcasing its longstanding partnership with the United Arab Emirates (UAE) Emirates Health Services (EHS), Children's Hospital of Philadelphia (CHOP) will exhibit thought-leading clinical research in the EHS booth at the Arab Health 2024 Exhibition and Congress , taking place this week in Dubai.
  • "CHOP has been treating patients worldwide with vascular anomalies for more than 25 years," said Dr. Denise Adams, Director of the Comprehensive Vascular Anomalies Program at Children's Hospital of Philadelphia.
  • "We are thrilled to be showcasing our multidisciplinary expertise and innovation in this field at Arab Health.
  • Arab Health 2024 marks the sixth year that EHS has invited CHOP to exhibit its pediatric innovation alongside EHS colleagues.

Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Risk, Constipation, Needle, Body surface area, Nausea, DNA, Cancer, T-ALL, Anatomy, Paresthesia, Cough, IIA, Hypoesthesia, Diarrhea, Fever, Fatigue, Infection, Bone marrow, ATC, Pain, Disease, Ageing, Somnolence, Periodic breathing, Cerebral edema, Edema, Enzyme, Safety, Anemia, Tumor lysis syndrome, Patient, Medical Subject Headings, Febrile neutropenia, Agency, Guanine, International, Paralysis, LBL, Neutropenia, Blood, Language, Myalgia, Dizziness, Thrombocytopenia, Nervous system, Thymus, Select, Vomiting, Peripheral neuropathy, Survival, Lymph, Extremities, System, Weakness, Headache, Brain, Swelling, European Medicines Agency, Convulsion, Growth, Cell, Lymphatic system, Medical device

Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

Retrieved on: 
Wednesday, December 13, 2023
Liver, Marketing, Hypogonadism, Risk, PRIME, FDA, TRT, WCS, Telehealth, Absorption, Fatigue, Health, Softgel, Site, SHGB, Conditional sentence, Obesity, Lymphatic system, DTC, Patient, Endocrine system, Erectile dysfunction, Pharmaceutical industry

KYZATREX, a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions, is one of only three FDA approved TRT treatments that is delivered orally--as opposed to the traditional, invasive, and inconvenient injection-based drug delivery protocol. KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.

Key Points: 
  • KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.
  • Testosterone deficiency is often first recognized through symptoms of fatigue or low energy, decreased sex drive, lower muscle mass and many other negative downstream impacts.
  • PRIME, powered by KYZATREX, can help men restore Testosterone to normal levels and improve how they feel.
  • KYZATREX marks a shift in the treatment paradigm and a meaningful opportunity for patients seeking to restore optimal testosterone levels.

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, November 9, 2023
Granzyme, Natural history, Antigen, Safety, Annual general meeting, DNA, Therapy, Risk, Peptide, Clinical trial, Mouse, Insurance, Patient, Research and development, Immunotherapy, PDAC, G&A, Lymph, Lymphatic system, RFS, Conference, BRAF, Cancer, Development, Pancreatic cancer, Death, SITC, V600E, Phase II, Neoplasm, AMP, OS, Society, AACR, Pharmaceutical industry, Vaccine, Amphiphile, Research, Elicio Berriz

R&D Expense: R&D expense for the third quarter of 2023 was $7.3 million, compared to $4.6 million for the third quarter of 2022.

Key Points: 
  • R&D Expense: R&D expense for the third quarter of 2023 was $7.3 million, compared to $4.6 million for the third quarter of 2022.
  • G&A Expense: G&A expense for the third quarter of 2023 was $3.5 million, compared to $1.2 million for the third quarter of 2022.
  • Net Loss and Net Loss per Share: Net loss for the third quarter of 2023 was $10.7 million, compared to $7.2 million for the third quarter of 2022.
  • Net loss per share for the third quarter of 2023 was $1.27 compared to $22.67 for the third quarter of 2022.

Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma

Retrieved on: 
Saturday, December 9, 2023
Oncology, Health, Genetics, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Tumor-associated macrophage, Associate, Toxicity, Weill Cornell Medicine, Progression-free survival, ASH, IND, Immunosuppression, Clinical trial, B-cell lymphoma, Patient, Tumor microenvironment, Pediatric Hematology and Oncology, Pharmacology, Lymph, Lymphatic system, TME, Therapy, Cancer, CD47, CMO, Drug resistance, 65th Street Yard, Doctor of Philosophy, Chemokine, Society, Overalls, Pharmaceutical industry, Vaccine, DLBCL, Hematology, Lymphoma, MD

Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882.

Key Points: 
  • Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882.
  • The new preclinical data covers results for SC-2882, Scenic’s first-in-class QPCTL inhibitor, as a potential new treatment approach for diffuse large B-cell lymphoma (DLBCL).
  • SC-2882 targets QPCTL and thereby inhibits the CD47-SIRPα “don’t eat me” checkpoint and lowers immune suppression in the tumor microenvironment.
  • Analysis of DLBCL patient datasets revealed that QPCTL expression negatively correlates with overall and progression-free survival.

Translational Science Is the Key to the Success of the Clinical Research

Retrieved on: 
Tuesday, December 5, 2023
NDA, Courage, Absorption, Research, R&D, Safety, Senior, AstraZeneca, Fundamental, Toxicity, Toxicology, IND, Disease, ADC, Clinical trial, EMA, CSO, DSM-IV codes, Patient, QCP, Pharmacology, Data analysis, Algorithm, Statera BioPharma, FDA, Science, Merck, Infection, Lymphatic system, Eli Lilly, PD-1, Statistics, Interview, Drug discovery, University, Survival, Antibody, GXP, Doctor of Philosophy, Biomarker, AI, ChromeOS, Pharmacotherapy, Drug development, Pharmaceutical industry, Fine chemical, Medical device, Medical imaging, Exelixis, Amgen

When serving as the Vice President of R&D at AstraZeneca, Dr. Roskos's leadership spanned across global clinical pharmacology, bioanalysis, biomarker, and translational science departments.

Key Points: 
  • When serving as the Vice President of R&D at AstraZeneca, Dr. Roskos's leadership spanned across global clinical pharmacology, bioanalysis, biomarker, and translational science departments.
  • He also held the position of Sr. VP at Exelixis, where he led the work of clinical pharmacology, bioanalysis & biomarkers, translational science and toxicity, pharmacology, drug genomics, bioinformatics, and translational medicine.
  • Amador offers comprehensive one-stop services, including clinical pharmacology, bioanalysis and biomarker research, clinical research, and regulatory affairs.
  • Translational science serves as a bridge between 'laboratory research' and 'clinical research', with a focus on patients and diseases.

Introducing The Plunge All-In: Redefining Aesthetics and Cooling Technology For Cold Water Therapy

Retrieved on: 
Wednesday, October 18, 2023
Luxury, Men, General Health, Interior Design, Home Goods, Family, Fitness & Nutrition, Consumer, Other Retail, Alternative Medicine, Construction & Property, Health, Specialty, Retail, Other Consumer, Women, Online Retail, Element, Temperature, Chronic pain, Thought, Lymph, The Plunge, Lymphatic system, Immersion, Entrepreneurship, Maintenance, Inflammation, Mental health, Multimedia, Immune system, Freezing, Norepinephrine, Depression, Cold, Anxiety, White, Longevity, Video game, Heating, ventilation, and air conditioning

Plunge , a leading innovator in home and spa wellness solutions, today announced the launch of its latest product, The Plunge All-In .

Key Points: 
  • Plunge , a leading innovator in home and spa wellness solutions, today announced the launch of its latest product, The Plunge All-In .
  • Introducing an entirely new iteration of their current cold plunge, the All-In seamlessly integrates Plunge’s newly engineered cold and clean system into the tub itself, providing a luxurious and sleek aesthetic.
  • View the full release here: https://www.businesswire.com/news/home/20231018293968/en/
    Introducing The Plunge All-In: Redefining Aesthetics and Cooling Technology For Cold Water Therapy (Photo: Business Wire)
    "Plunge has always been at the front of the line when it comes to redefining home wellness, and the Plunge All-In is a testament to our commitment to excellence within innovation and design," said Michael Garrett, Co-Founder and CEO of Plunge.
  • "We created our first cold plunge for ourselves, but the All-In was driven directly from our customers.

Chan Zuckerberg Biohub New York Will Build Technologies To Monitor Health and Eradicate Disease

Retrieved on: 
Wednesday, October 18, 2023
Science, Rockefeller University, Treatment, Lymphatic system, Cell, Artificial intelligence, Disease, Economic development, Private sector, Partnership, Hospital, Priscilla Chan, Chan Zuckerberg Initiative, New York City Economic Development Corporation, Health, Chan Zuckerberg Biohub, Physician, Workforce, Immune system, Medicine, University, Biology, Machine learning, Columbia University, Blood, Ageing, NYCEDC, CZI, Parkinson's disease, Genetics, Research, City, Tissue, Learning, Network, Travel, State government, Biomedical Research, Autoimmunity, Inflammation, Yale University, IBA Lifesciences, National Cancer Institute, Alzheimer's disease, Vaccine, Pharmaceutical industry, Management, Cancer

REDWOOD CITY, Calif., Oct. 18, 2023 /PRNewswire/ -- Today, the Chan Zuckerberg Initiative (CZI) announced the launch of a new biomedical research hub in New York City that will catalyze collaboration between leading scientific and technology institutions in the area, with the goal of solving grand scientific challenges on 10- to 15-year time horizons. The Chan Zuckerberg Biohub New York (CZ Biohub NY) brings together Columbia University, The Rockefeller University, and Yale University to create new technologies to characterize and bioengineer immune cells — with the ultimate goal of creating disease-specific "cellular endoscopes" that can detect early stages of disease in cells, monitor cell changes, and resolve diseases before they become untreatable.

Key Points: 
  • The CZ Biohub NY is the fourth research institute in the Chan Zuckerberg Biohub Network , a groundbreaking collaborative model for scientific research.
  • The Network includes the first CZ Biohub, in San Francisco , a second in Chicago , and the Chan Zuckerberg Institute for Advanced Biological Imaging in Redwood City, California.
  • In addition to the funding from CZI, the State of New York and New York City are also contributing $10 million each to the CZ Biohub NY.
  • "With a world-class faculty, cutting-edge research, and a time-tested model for innovation, the Chan Zuckerberg Biohub will help us continue to build the future of medicine in New York," Governor Hochul said.